Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2018, Article ID 5237950, 9 pages
https://doi.org/10.1155/2018/5237950
Research Article

Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents

1Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China
2Laboratories of Translational Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China
3Department of Nuclear Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
4Department of Nuclear Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China
5Department of Natural Medicinal Chemistry and Jiangsu Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China
6Department of Criminal Science and Technology, Nanjing Forest Police College, Nanjing 210023, China

Correspondence should be addressed to Yunliang Qiu; nc.ude.cpfn@lyuiq and Qiaomei Jin; moc.361@yxmqj

Received 2 August 2017; Revised 17 October 2017; Accepted 4 December 2017; Published 26 February 2018

Academic Editor: Giancarlo Pascali

Copyright © 2018 Dongjian Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Ben-Haim and P. Ell, “18F-FDG PET and PET/CT in the evaluation of cancer treatment response,” Journal of Nuclear Medicine, vol. 50, no. 1, pp. 88–99, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge, “From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors,” Journal of Nuclear Medicine, vol. 50, no. 1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. M. Chang, H. J. Lee, J. M. Goo, J. J. Lee, J. Chung, and J. Im, “False positive and false negative FDG-PET scans in various thoracic diseases,” Korean Journal of Radiology, vol. 7, no. 1, pp. 57–69, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Elvas, C. Vangestel, K. Pak et al., “Early prediction of tumor response to treatment: Preclinical validation of 99mTc-Duramycin,” Journal of Nuclear Medicine, vol. 57, no. 5, pp. 805–811, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Perreault, S. Richter, C. Bergman, M. Wuest, and F. Wuest, “Targeting Phosphatidylserine with a 64Cu-Labeled Peptide for Molecular Imaging of Apoptosis,” Molecular Pharmaceutics, vol. 13, no. 10, pp. 3564–3577, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Stammes, V. T. Knol-Blankevoort, L. J. Cruz et al., “Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging,” Molecular Imaging and Biology, vol. 18, no. 6, pp. 905–915, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. T. H. Witney, A. Hoehne, R. E. Reeves et al., “A systematic comparison of 18F-C-SNAT to established radiotracer imaging agents for the detection of tumor response to treatment,” Clinical Cancer Research, vol. 21, no. 17, pp. 3896–3905, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Kwak, Y. S. Ha, N. Soni et al., “Apoptosis imaging studies in various animal models using radio-iodinated peptide,” Apoptosis, vol. 20, no. 1, pp. 110–121, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. H. L. Wang, X. L. Tang, G. H. Tang et al., “Noninvasive positron emission tomography imaging of cell death using a novel small-molecule probe, 18F labeled bis(zinc(II)-dipicolylamine) complex,” Apoptosis, vol. 18, no. 8, pp. 1017–1027, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Song, C. Xiong, W. Lu, G. Ku, G. Huang, and C. Li, “Apoptosis imaging probe predicts early chemotherapy response in preclinical models: a comparative study with 18F-FDG PET,” Journal of Nuclear Medicine, vol. 54, no. 1, pp. 104–110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Wang, S. Purushotham, J.-Y. Lee et al., “In vivo imaging of tumor apoptosis using histone H1-targeting peptide,” Journal of Controlled Release, vol. 148, no. 3, pp. 283–291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. D. W. Siemann, “The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents,” Cancer Treatment Reviews, vol. 37, no. 1, pp. 63–74, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M.-J. Pérez-Pérez, E.-M. Priego, O. Bueno, M. S. Martins, M.-D. Canela, and S. Liekens, “Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: an Approach to Targeting Tumor Growth,” Journal of Medicinal Chemistry, vol. 59, no. 19, pp. 8685–8711, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. D. W. Siemann, D. J. Chaplin, and P. A. Walicke, “A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P),” Expert Opinion on Investigational Drugs, vol. 18, no. 2, pp. 189–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Jaroch, M. Karolak, P. Górski et al., “Combretastatins: in vitro structure-activity relationship, mode of action and current clinical status,” Pharmacological Reports, vol. 68, no. 6, pp. 1266–1275, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. B. A. Smith and B. D. Smith, “Biomarkers and molecular probes for cell death imaging and targeted therapeutics,” Bioconjugate Chemistry, vol. 23, no. 10, pp. 1989–2006, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. A. Neves and K. M. Brindle, “Imaging cell death,” Journal of Nuclear Medicine, vol. 55, no. 1, pp. 1–4, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Dasari, S. Lee, J. Sy et al., “Hoechst-IR: An imaging agent that detects necrotic tissue in vivo by binding extracellular DNA,” Organic Letters, vol. 12, no. 15, pp. 3300–3303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Leblond, S. C. Davis, P. A. Valdés, and B. W. Pogue, “Pre-clinical whole-body fluorescence imaging: review of instruments, methods and applications,” Journal of Photochemistry and Photobiology B: Biology, vol. 98, no. 1, pp. 77–94, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. K. Willmann, N. van Bruggen, L. M. Dinkelborg, and S. S. Gambhir, “Molecular imaging in drug development,” Nature Reviews Drug Discovery, vol. 7, no. 7, pp. 591–607, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. B. A. Smith, S. T. Gammon, S. Xiao et al., “In vivo optical imaging of acute cell death using a near-infrared fluorescent zinc-dipicolylamine probe,” Molecular Pharmaceutics, vol. 8, no. 2, pp. 583–590, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Yao, K. Ren, C. Jiang et al., “Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo,” Tumor Biology, vol. 36, no. 11, pp. 8499–8510, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. R. P. Mason, D. Zhao, L. Liu, M. L. Trawick, and K. G. Pinney, “A perspective on vascular disrupting agents that interact with tubulin: Preclinical tumor imaging and biological assessment,” Integrative Biology, vol. 3, no. 4, pp. 375–387, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Shao, Y. Ni, J. Zhang et al., “Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors,” PLoS ONE, vol. 8, no. 12, Article ID e82649, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Shao, Y. Ni, X. Dai et al., “Diffusion-weighted MR imaging allows monitoring the effect of combretastatin A4 phosphate on rabbit implanted VX2 tumor model: 12-Day dynamic results,” European Journal of Radiology, vol. 81, no. 3, pp. 578–583, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Zhao, E. Richer, P. P. Antich, and R. P. Mason, “Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI,” The FASEB Journal, vol. 22, no. 7, pp. 2445–2451, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Liu, R. P. Mason, and B. Gimi, “Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts,” Cancer Letters, vol. 356, no. 2, pp. 462–469, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Huang, H. H. Chen, H. Yuan et al., “Molecular MRI of acute necrosis with a novel DNA-binding gadolinium chelate kinetics of cell death and clearance in infarcted myocardium,” Circulation: Cardiovascular Imaging, vol. 4, no. 6, pp. 729–737, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Dasari, A. P. Acharya, D. Kim et al., “H-Gemcitabine: A new gemcitabine prodrug for treating cancer,” Bioconjugate Chemistry, vol. 24, no. 1, pp. 4–8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. R. S. Khan, M. D. Martinez, J. C. Sy et al., “Targeting extracellular DNA to deliver IGF-1 to the injured heart,” Scientific Reports, vol. 4, article no. 4257, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Kim, J. Park, Y. S. Youn, K. T. Oh, J. H. Bae, and E. S. Lee, “Hoechst 33258-conjugated hyaluronated fullerene for efficient photodynamic tumor therapy and necrotic tumor targeting,” Journal of Bioactive and Compatible Polymers, vol. 30, no. 3, pp. 275–288, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. Q. Luo, Q. Jin, C. Su et al., “Radiolabeled Rhein as Small-Molecule Necrosis Avid Agents for Imaging of Necrotic Myocardium,” Analytical Chemistry, vol. 89, no. 2, pp. 1260–1266, 2016. View at Publisher · View at Google Scholar
  34. X. Duan, Z. Yin, C. Jiang et al., “Radioiodinated hypericin disulfonic acid sodium salts as a DNA-binding probe for early imaging of necrotic myocardium,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 117, pp. 151–159, 2017. View at Publisher · View at Google Scholar
  35. F. G. Blankenberg, “In vivo detection of apoptosis,” Journal of Nuclear Medicine, vol. 49, no. 6, pp. 81–95, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Kim, D. Kim, Y. Lee, H. Jeon, B.-H. Lee, and S. Jon, “Conversion of low-affinity peptides to high-affinity peptide binders by using a β-hairpin scaffold-assisted approach,” ChemBioChem, vol. 16, no. 1, pp. 43–46, 2015. View at Publisher · View at Google Scholar · View at Scopus